Diagnostic Criteria and Genetic Testing

Confirming a diagnosis of Familial Partial Lipodystrophy type 4 (FPLD4) is a two-step process that combines clinical suspicion based on what a doctor sees on your body with genetic confirmation found in your DNA. Because FPLD4 is so rare, careful evaluation by an experienced clinician is critical ^[1][2].

The Starting Point: Clinical Suspicion

Experts, such as those in the Brazilian consensus group, have developed specific frameworks to help doctors suspect FPLD. For a clinical suspicion, doctors look for a physical finding like lower-limb lipoatrophy (loss of fat in the legs) ^[2].

In addition to this fat loss, a doctor looks for at least one “associated feature,” which might include:

• Severe Insulin Resistance: High blood sugar, diabetes, or acanthosis nigricans (dark, velvety patches of skin) ^[2][1].
• Abnormal Blood Fats: Very high triglycerides or low “good” (HDL) cholesterol ^[2].
• Liver Health: Hepatic steatosis (fatty liver disease) ^[2].
• Reproductive Signs: Symptoms of Polycystic Ovary Syndrome (PCOS) or excess hair growth (hirsutism) ^[3].

Objective Imaging: DXA and MRI

To move beyond a visual exam, doctors may use imaging to measure exactly how much fat you have and where it is located. These are supportive or research findings and are population-dependent, not universal requirements:

• DXA (Dual-energy X-ray Absorptiometry): A DXA scan can measure body composition. In some populations of women with partial lipodystrophy, having lower-limb fat below the 1st percentile for their age and sex is an objective indicator used ^[4].
• MRI (Magnetic Resonance Imaging): A pelvic MRI can measure gluteal fat thickness. Some research suggests that a fat thickness of 13 mm or less in the buttocks is supportive of an FPLD diagnosis ^[5].
• Skinfold Measurements: Calipers can measure the thickness of fat under your skin. A thigh skinfold of 20 mm or less in women has been used in some studies as a supporting measurement ^[6].

It is important to remember that these are not strict “pass/fail” diagnostic cutoffs, and a diagnosis should not rely on a single measurement.

The Genetic Piece: Interpreting PLIN1

The assignment of the specific FPLD4 subtype requires appropriate interpretation of a pathogenic PLIN1 variant. The most important thing to know is that not all mutations in the PLIN1 gene cause the disease.

Genetic reports may use technical terms that can be confusing:

• Pathogenic Frameshift Variants: These are specific mutations that “shift” the DNA’s reading frame, typically leading to a malfunctioning protein. These are the variants most strongly linked to the FPLD4 body type ^[3].
• Null or Truncating Variants: These are mutations predicted to stop the protein from being made entirely. Surprisingly, many people carry these “null” variants without ever developing lipodystrophy ^[7][8]. A truncating prediction alone does not confirm the diagnosis.
• Variant of Uncertain Significance (VUS): This means the lab found a change in the gene, but there is not enough evidence to know if it causes disease. A VUS should not be treated as a diagnosis and should not be used alone to guide predictive testing or treatment.

Because of this, a genetic test result alone is not enough for a diagnosis. While seeing if the mutation “segregates” (travels) with the condition in other family members can help interpret a VUS, family segregation is often unavailable or incomplete ^[3][9]. Working with a genetic counselor is highly recommended.

Your Diagnostic Checklist

A complete and accurate diagnostic report for FPLD4 should combine both clinical and genetic evidence.

1. Clinical Description: A detailed record of the age when fat loss started and exactly which areas of the body are affected (e.g., “postpubertal loss of fat in limbs and buttocks”) ^[3].
2. Specific Variant Data: The exact name of your PLIN1 mutation (using cDNA and protein nomenclature) and its “zygosity” (whether you have one or two copies of the mutation) ^[9].
3. Laboratory Classification: Whether the lab considers the variant “pathogenic,” “likely pathogenic,” or a “variant of uncertain significance (VUS)” ^[9].
4. Body Composition Data: Optional results from your DXA or MRI scans, including regional fat percentages or ratios ^[10].
5. Metabolic Profile: A summary of your fasting glucose, insulin levels, triglycerides, and liver enzyme tests ^[3][11].
6. Family History: A review showing if any relatives have similar physical or metabolic traits ^[3].

By combining these different types of evidence, your medical team can properly confirm a diagnosis and tailor your treatment.